Literature DB >> 15530699

Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.

Changpin Zhang1, Robert F Pass.   

Abstract

Preabsorption of sera with cytomegalovirus (CMV) glycoprotein B (gB) prior to testing for CMV IgG antibody was evaluated for detection of CMV infection during CMV gB vaccine clinical trials. Although, 98.2% of 109 CMV gB vaccine recipients were seropositive with a standard assay, preabsorption of sera with gB reduced their CMV antibody to extremely low levels compared with subjects with CMV infection. One subject who acquired CMV during a vaccine trial was easily identified by gB-absorbed CMV IgG results. The gB-absorbed CMV IgG antibody assay is a promising approach for screening CMV gB vaccine trial participants for CMV infection.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15530699     DOI： 10.1016/j.vaccine.2004.06.027

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

Authors:  Kristina Abel; Joy Martinez; Yujuan Yue; Simon F Lacey; Zhongde Wang; Lisa Strelow; Anindya Dasgupta; Zhongqi Li; Kimberli A Schmidt; Kristie L Oxford; Basel Assaf; Jeffrey A Longmate; Don J Diamond; Peter A Barry
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

Review 2.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

3.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

4.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 5.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 6.  Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Authors:  Robert F Pass
Journal:  J Clin Virol       Date:  2009-07-31       Impact factor: 3.168

7.  Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Authors:  Lin Xia; Ruopeng Su; Zhiqiang An; Tong-Ming Fu; Wenxin Luo
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

Review 8.  Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth.

Authors:  Miranda Li; Alyssa Brokaw; Anna M Furuta; Brahm Coler; Veronica Obregon-Perko; Ann Chahroudi; Hsuan-Yuan Wang; Sallie R Permar; Charlotte E Hotchkiss; Thaddeus G Golos; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

Review 9.  Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity.

Authors:  Hsuan-Yuan Wang; Sarah M Valencia; Susanne P Pfeifer; Jeffrey D Jensen; Timothy F Kowalik; Sallie R Permar
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.818

Review 10.  Cytomegalovirus vaccine: phase II clinical trial results.

Authors:  F Rieder; C Steininger
Journal:  Clin Microbiol Infect       Date:  2014-01-22       Impact factor: 8.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.